Calcitonin and Procalcitonin in Patients with Medullary Thyroid Cancer or Bacterial Infection

被引:1
|
作者
Kaczka, Krzysztof [1 ]
Mikosinski, Slawomir [2 ]
Fendler, Wojciech [3 ]
Celnik, Agnieszka [1 ]
Pomorski, Lech [1 ]
机构
[1] Med Univ Lodz, Dept Gen & Oncol Surg, PL-95100 Zgierz, Poland
[2] Maria Sklodowska Curie Mem Hosp, Dept Nucl Med & Oncol Endocrinol, Zgierz, Poland
[3] Med Univ Lodz, Dept Pediat Oncol Hematol & Diabetol, PL-95100 Zgierz, Poland
来源
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE | 2012年 / 21卷 / 02期
关键词
procalcitonin; calcitonin; medullary thyroid cancer; SERUM CALCITONIN; ROUTINE MEASUREMENT; CARCINOMA; PREVALENCE; DIAGNOSIS; THERAPY; MARKERS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives. To evaluate procalcitonin (PCT) utility as a marker of medullary thyroid cancer (MTC). Material and Methods. Calcitonin (CT) and PCT levels were measured in MTC patients and patients with serious bacterial infections. 70 patients were enrolled in the study: 6 MTC active patients: 4 with disseminated, unreoperable disease and 2 re-operated patients, in whom markers were checked before and after surgery; 23 MTC patients in remission after radical surgery; 11 non-toxic nodular goiter (NTNG) patients; 30 patients with severe, bacterial infection or sepsis. Results. All MTC active patients had greatly elevated CT and PCT levels. In two re-operated patients, marker levels decreased but were still above the reference range. In 15 MTC patients in remission, the levels of either marker were not increased. Both markers were slightly increased in 3 patients in this group, while CT was elevated in 5 patients. In all but 1 patient in the NTNG group, both marker levels were not elevated. Among patients with bacterial infection, PCT and CT levels showed no increase in 8 patients, both markers were elevated in 10 patients, and an increase of PCT levels was seen in 10 patients while of CT only in 2 patients. Correlations between CT and PCT values were very strong in MTC patients (r = 0.95; p = 0.004 for active MTC, r = 0.60; p = 0.002 for MTC patients in remission) and in patients with NTNG (r = 0.77; p = 0.02). In patients with infection, both parameters were completely independent (r = 0.002; p = 0.99). Conclusions. PCT measurement could be an alternative to CT measurement for evaluation of MTC status (Adv Clin Exp Med 2012, 21, 2, 169-178).
引用
收藏
页码:169 / 178
页数:10
相关论文
共 50 条
  • [1] Can procalcitonin be useful for medullary thyroid cancer?
    Kaczka, Krzysztof
    Mikosinski, Slawomir
    Fendler, Wojciech
    Jalocha-Kaczka, Anna
    Pomorski, Lech
    ENDOKRYNOLOGIA POLSKA, 2010, 61 (05) : 430 - 436
  • [2] Diagnostic Performance of Preoperative Calcitonin and Procalcitonin Tests for Differential Diagnosis of Medullary Thyroid Cancer
    Jeong, Il Youb
    Yun, Hyeok Jun
    Kim, Seok-Mo
    Park, Yongjung
    DIAGNOSTICS, 2024, 14 (16)
  • [3] Comparative assessment of calcitonin stimulation test using calcium gluconate and pentagastrin and the usefulness of procalcitonin basic and post-stimulation concentrations in the diagnosis of patients after surgery for medullary thyroid cancer
    Kowalska, Aldona
    Lizis-Kolus, Katarzyna
    Gasior-Perczak, Danuta
    Palyga, Iwona
    Sluszniak, Anna
    Sluszniak, Janusz
    Antczak, Grazyna
    Lizis, Pawel
    Mezyk, Ryszard
    Gozdz, Stanislaw
    NEUROENDOCRINOLOGY LETTERS, 2016, 37 (07) : 485 - 490
  • [4] Calcitonin determination for early diagnosis of medullary thyroid cancer
    Karges, W.
    CHIRURG, 2010, 81 (07): : 620 - +
  • [5] Basal and Stimulated Calcitonin and Procalcitonin by Various Assays in Patients with and without Medullary Thyroid Cancer
    Kratzsch, Juergen
    Petzold, Anne
    Raue, Friedhelm
    Reinhardt, Walter
    Broecker-Preuss, Martina
    Goerges, Rainer
    Mann, Klaus
    Karges, Wolfram
    Morgenthaler, Nils
    Luster, Markus
    Reiners, Christoph
    Thiery, Joachim
    Dralle, Henning
    Fuhrer, Dagmar
    CLINICAL CHEMISTRY, 2011, 57 (03) : 467 - 474
  • [6] Clinical performance of calcitonin and procalcitonin Elecsys® immunoassays in patients with medullary thyroid carcinoma
    Giovanella, Luca
    Fontana, Martina
    Keller, Franco
    Verburg, Frederik A.
    Ceriani, Luca
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (04) : 743 - 747
  • [7] Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules
    Giovanella, Luca
    Verburg, Frederik A.
    Imperiali, Mauro
    Valabrega, Stefano
    Trimboli, Pierpaolo
    Ceriani, Luca
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (07) : 1477 - 1481
  • [8] Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review
    Karagiannis, Apostolos K. A.
    Girio-Fragkoulakis, Constantine
    Nakouti, Theodora
    ANTICANCER RESEARCH, 2016, 36 (08) : 3803 - 3810
  • [9] The role of procalcitonin in the follow-up of medullary thyroid cancer
    Censi, Simona
    Manso, Jacopo
    Benvenuti, Teresa
    Piva, Ilaria
    Iacobone, Maurizio
    Mondin, Alberto
    Torresan, Francesca
    Basso, Daniela
    Crivellari, Gino
    Zovato, Stefania
    Mian, Caterina
    EUROPEAN THYROID JOURNAL, 2023, 12 (01)
  • [10] Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen
    Wolinski, Kosma
    Kaznowski, Jaroslaw
    Klimowicz, Aleksandra
    Maciejewski, Adam
    Lapinska-Cwojdzinska, Dagny
    Gurgul, Edyta
    Car, Adrian D.
    Fichna, Marta
    Gut, Pawel
    Gryczynska, Maria
    Ruchala, Marek
    ENDOKRYNOLOGIA POLSKA, 2017, 68 (04) : 434 - 437